Data investigation

Not Taking It and Not Tolerating It

Real-world studies usually measure adherence and stopping separately, with every kind of stopping counted the same way. That merges someone whose body cannot tolerate the drug with someone not taking it reliably. A Scottish study separated them and found different predictors.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

Real-world studies of these drugs usually measure adherence and stopping as separate outcomes, with every kind of stopping counted the same way. That merges two different situations: someone whose body cannot tolerate the drug, and someone who is not taking it reliably. A Scottish study combined the measures to separate them, and found they have different predictors.[1] So they need different responses, yet the usual measures do not tell them apart.

Why splitting them matters

A person who vomits every time they inject and gives up has a pharmacological problem. A person who keeps meaning to refill and does not has a logistical one. Both appear in a database as a discontinuation, and both get counted in the persistence figures this register has reported.

The interventions are opposite. The first needs a slower titration, a lower dose, or a different drug, and that kind of change has randomized evidence behind it. The second needs reminders, cheaper refills, or fewer barriers between the prescription and the pharmacy. Applying either to the wrong person achieves nothing.

This study classified every treatment start in a national diabetes database into five mutually exclusive groups over one year: adherent, poor adherence, and three ways of discontinuing including a proxy for intolerance.

The two profiles

What predicted each pattern among people starting a GLP-1.[1]
PatternAssociated with
Poor adherenceYounger age; previous GLP-1 use
IntoleranceLower BMI; female sex; more advanced chronic kidney disease
Two ways of ending treatment, and almost nothing in common between them.
The lower-BMI finding has an obvious mechanism, and it is one this drug class shares. These medicines are dosed as fixed amounts, the same number of milligrams whether someone weighs 70 kg or 140. A lighter person therefore receives roughly twice the drug per kilogram of body weight, at the same nominal dose, and gastrointestinal effects scale with exposure.

If that is what is happening, it is directly actionable: the people most likely to be driven off these drugs by side effects are the ones for whom a slower or lower titration should be considered first. Nothing in this study tests that, but it is the obvious hypothesis the study generates.

The chronic kidney disease association is less clear-cut. The authors suggest it may apply mainly to the drugs the kidneys clear, exenatide and lixisenatide, rather than to the whole class, and lixisenatide was the drug most associated with intolerance here.[1]

The finding that turns up twice

Female sex predicted intolerance here. In a separate US cohort we covered, women had lower odds of both persistence and adherence over twelve months (see less than half are still taking it).

The two studies used different countries, databases and measures, and they point the same way. That is worth more than either finding alone. It also runs against how this field is usually framed: trials over-recruit women, and the public conversation about these drugs is largely about women taking them.

Neither study explains it. If the lower-BMI mechanism is real, part of the answer may be that women are on average lighter and therefore receive more drug per kilogram at the same dose. That would make the sex finding a body-size finding in disguise. It remains a hypothesis, and testing it would require dosing by weight, which nobody does. One semaglutide analysis found women reported more nausea than men even at matched drug levels; see GLP-1 side effects in women vs men.

The drug-by-drug part, and why to hold it loosely

Newer agents showed more favorable usage patterns. Poor adherence was more frequent with liraglutide, lixisenatide and exenatide than with semaglutide, and intolerance was most common with lixisenatide.

That comparison is confounded with time. The older agents were prescribed in an earlier era, to different patients, under different expectations, often as daily injections rather than weekly ones. Whether semaglutide is easier to stay on, or simply arrived when prescribing and support had improved, this design cannot separate.

One more caution on the whole analysis: intolerance here is a proxy, inferred from the shape of prescribing records rather than read from a recorded diagnosis. Nobody wrote down that these patients could not tolerate the drug; the pattern of their prescriptions suggested it.

Frequently Asked Questions

Because they need opposite responses. Someone who cannot tolerate the drug needs a slower titration, a lower dose or a different agent; someone not taking it reliably needs reminders, cheaper refills or fewer barriers. Both look identical in a database that only records stopping.
People with lower BMI, women, and those with more advanced chronic kidney disease. Poor adherence had a different profile: younger age and previous GLP-1 use.
These drugs are dosed as fixed amounts regardless of body size, so a lighter person receives roughly twice the drug per kilogram at the same nominal dose. Gastrointestinal effects scale with exposure. The kidney disease link may be specific to the drugs the kidneys clear, such as lixisenatide.
Two independent datasets point that way: this Scottish cohort for intolerance, and a US cohort for persistence and adherence. Neither explains it, and if the body-size mechanism is real, part of the answer may be that women are on average lighter and receiving more drug per kilogram.
It showed more favorable usage patterns, but that comparison is confounded with era. The older agents were prescribed to different patients under different expectations, often daily rather than weekly.

References

  1. 1.Donnelly LA, Singh K, McCrimmon RJ, et al. One-year usage patterns of SGLT-2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes in a real-world population Diabetes, Obesity and Metabolism. 2026. PMID: 41189335.

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

MyDrHank

An oral route if you will not self-inject

9.0

YourEra

Semaglutide at $99/month, well below the typical price

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →